Cryopyrin-associated periodic syndromes are categorized as a spectrum of three autoinflammatory diseases, namely familial cold auto-inflammatory syndrome, Muckle-Wells syndrome and chronic infantile neurological cutaneous articular syndrome. All are caused by mutations in the NLRP3 gene coding for cryopyrin and result in active interleukin-1 release: their rarity and shared clinical indicators involving skin, joints, central nervous system and eyes often mean that correct diagnosis is delayed. Onset occurs early in childhood, and life-long therapy with interleukin-1 blocking agents usually leads to tangible clinical remission and inflammatory marker normalization in a large number of patients, justifying the need to facilitate early diagnosis and thus avoid irreversible negative consequences for tissues and organs.
AgostiniLMartinonFBurnsKMcDermottMFHawkinsPNTschoppJ. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity2004;20:319–25.
5.
HoffmanHMMuellerJLBroideDHWandererAAKolodnerRD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet2001; 29:301–5.
6.
ShinkaiKMcCalmontTHLeslieKS. Cryopyrin-associated periodic syndrome and autoinflammation. Clin Exp Dermatol2008; 33:1–9.
7.
HoffmanHMWandererAABroideDH. Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol2001; 108:615–20.
MuckleTJWellsM. Urticaria, deafness, and amyloidosis: A new heredo-familial syndrome. Q J Med1962; 31:235–48.
10.
LequerreTVittecoqOSaugier-VeberP. A cryopyrin-associated periodic syndrome with joint destruction. Rheumatology (Oxford)2007; 46:709–14.
11.
LorberJ. Syndrome for diagnosis: Dwarfing, persistently open fontanelle; recurrent meningitis; recurrent subdural effusions with temporary alternate-sided hemiplegia; high-tone deafness; visual defect with pseudopapilloedema; slowing intellectual development; recurrent acute polyarthritis; erythema marginatum, splenomegaly and iron-resistant hypochromic anaemia. Proc R Soc Med1973; 66:1070–71.
12.
PrieurAM. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol2001; 19:103–6.
KitleyJLLachmannHJPintoAGinsbergL. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology2010; 74: 1267–70.
15.
AksentijevichINowakMMallahM. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multi system inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum2002; 46:3340–48.
16.
ArendWPPalmerGGabayC. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev2008; 223: 20–38.
17.
MartinonFBurnsKTschoppJ. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell2002; 102:417–26.
18.
JesusAASilvaCASegundoGR. Phenotype-genotype analysis of cryopyrin-associated periodic syndromes (CAPS): Description of a rare non-exon 3 and a novel CIAS1 missense mutation. J Clin Immunol2008; 28:134–38.
19.
FrenkelJvan KempenMJKuisWvan AmstelHK. Variant chronic infantile neurologic, cutaneous, articular syndrome due to a mutation within the leucine-reach repeat domain of CIAS1. Arthritis Rheum2004; 50:2719–20.
20.
AgannaEMartinonFHawkinsPN. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum2002; 46:2445–52.
21.
AksentijevichIPutnamDCRemmersEF. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum2007; 56: 1273–85.
22.
CuissetLJeruIDumontB. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: Epidemiological study and lessons from eight year of genetic analysis in France. Ann Rheum Dis2011; 70:495–9.
PietzschJHoppmannS. Human S100A12: A novel key player in inflammation?Amino Acids2009; 36: 381–89.
25.
Aït-AbdesselamTLequerréTLegallicierBFrançoisALe LoëtXVittecoqO. Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. Joint Bone Spine2010; 77:616–17.
26.
HaasNKüsterWZuberbierTHenzBM. Muckle-Wells syndrome: Clinical and histological skin findings compatible with cold air urticaria in a large kindred. Br J Dermatol2004; 151:99–104.
27.
HoffmanHMWolfeFBelomestnovPMellisSJ. Cryopyrin-associated periodic syndromes: Development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr Med Res Opin2008; 24:2531–43.
28.
RossJBFinlaysonLAKlotzPJ. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg2008; 12:8–16.
29.
O'ConnellSMO'ReganGMBolgerT. Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol2007; 24:85–9.
30.
HoffmanHMRosengrenSBoyleDL. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet2004; 364: 1779–85.
31.
HawkinsPNLachmannHJAgannaEMcDermottMF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum2004; 50:607–12.
32.
MiraultTLaunayDCuissetL. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum2006; 54: 1697–700.
33.
Goldbach-ManskyRDaileyNJCannaSW. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med2006; 355:581–92.
34.
LeporeLPaloniGCaorsiR. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr2010; 157:310–15.
35.
YuJRLeslieKS. Cryopyrin-associated periodic syndrome: An update on diagnosis and treatment response. Curr Allergy Asthma Rep2011; 11:12–20.
36.
RiganteDStabileAMinnellaA. Postinflammatory retinal dystrophy in CINCA syndrome. Rheumatol Int2010; 30:389–93.
37.
Goldbach-ManskyRShroffSDWilsonM. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum2008; 58:2432–42.
38.
HoffmanHM. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther2009; 9:519–31.
39.
SavicSMcDermottMR, Inflammation: Canakinumab for the cryopyrin-associated periodic syndromes. Nat Rev Rheumatol2009; 5:529–30.
40.
LachmannHJKone-PautIKuemmerle-DeschnerJB. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med2009; 360:2416–25.
